EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 137 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... December 7, 2021 Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... February 24, 2025 Reflecting on COVID-19 and the Importance of Providing Information to People... July 21, 2022 5-Year-Old Boy Meets Generous Stem Cell Donor Who Cured Him October 13, 2021 Load more HOT NEWS With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era Coping With Life After a Bone Marrow Transplant: A Survivor’s Story Reduction Not Only in Recurrences, but Also in Mortality, Observed for... Por qué no voy a “superar” los efectos a largo plazo...
